GABRB1
Gamma-aminobutyric acid receptor subunit beta-1
As of the edition of 20 October 2026, GABRB1 (gamma-aminobutyric acid receptor subunit beta-1, UniProt P18505) has 13 drugs tested at it and 10 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P18505
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Eye; Immune system; Infections; Injuries; Nutrition and metabolism
- Registered trials of its drugs
- 31
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 12 |
| Withdrawn from market | 1 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Zaleplon | Marketed | Phase 4 | none listed |
| Thiopental | Marketed | Phase 4 | none listed |
| Primidone | Marketed | Phase 2 | none listed |
| Pentobarbital | Withdrawn from market | Phase 3 | none listed |
| Methohexital | Marketed | Phase 4 | none listed |
| Clomethiazole | Marketed | Phase 3 | none listed |
| Butabarbital | Marketed | No phase stated | none listed |
| Butalbital | Marketed | No phase stated | none listed |
| Meprobamate | Marketed | No phase stated | none listed |
| Metharbital | Marketed | No phase stated | none listed |
| Secobarbital | Marketed | No phase stated | none listed |
| Talbutal | Marketed | No phase stated | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 8 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Apsen Farmaceutica | Route B |
The other 8 companies at GABRB1
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at GABRB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.